Navigation Links
Medivir Interim Report, 1 January - 30 September 2010

Medivir Interim Report, 1 January - 30 September 2010 -- HUDDINGE, Sweden, October 22, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Earnings Click to view news release full screen  

Medivir Interim Report, 1 January - 30 September 2010


HUDDINGE, Sweden, October 22, 2010 /PRNewswire/ -- Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

Financial Highlights 1 January - 30 September - Consolidated net sales were SEK 54.7 (24.5) m. - The consolidated profit/loss for the period was SEK -77.6 (-93.0) m. - Earnings per share for the period were SEK -3.30 (-4.46). - Cash flow from operating activities was SEK -35.0 (-104.8) m. - Cash and cash equivalents and investments in securities etc. at the end of the period were SEK 421.8 (176.1) m. Third Quarter Operational Highlights - Positive phase 2b interim PILLAR data presented in July on TMC435, Medivir's lead development drug for Hepatitis C (HCV) infections. These data demonstrate that TMC435 has potent antiviral effect and an attractive safety profile, properties making TMC435 the best in class investigational HCV drug under development. - To realise the maximum commercial value in different markets, another two distribution partnering deals have been entered for Xerclear(R)/Xerese(R), an innovative treatment for cold sores, with Daewoong and Luxembourg. This is in addition to Medivir's agreement with GlaxoSmithKline for OTC sales in Europe and other key territories and the agreement with Meda for Rx sales in North America. During the ongoing preparations for this introduction to the market, the launch of Xerese(R) in North America has been confirmed for the first quarter of 2011. - The early-stage antiviral project portfolio, focusing on new approaches to treat HCV and other infectious diseases, is progressing well. Post Period End Highlights - Medivir announced in early October that new results with TMC435 will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston in late October 2010. This will be via a late breaking oral presentation on TMC435 phase 2b ongoing studies and four additional poster presentations on data regarding efficacy and safety and pharmacokinetic data of TMC435.

A comment from Ron Long, Medivir's CEO:

"Medivir has continued to make important progress in the third quarter of this year on the route towards becoming a successful specialty pharmaceutical company operating on an international stage. Our lead development product, TMC435, has blockbuster potential in the exciting Hepatitis C therapy arena. TMC435 is demonstrating extremely positive data in phase 2b trials, with clear competitive advantages. We look forward to the presentation of week-24 interim results at the AASLD meeting in Boston in October.

We have also worked hard during this quarter to ensure that we increase the commercial value of our innovative cold sore product Xerclear(R)/Xerese(R ) and have signed two further agreements in different geographic markets.

The success demonstrated with Xerclear(R) and Xerese(R) shows Medivir's ability to develop and commercialize products and collaborate with blue-chip partners.

Following the successful rights issue concluded in June 2010 we are in healthy financial position and have therefore been able to remain focused on developing our exciting portfolio of early-phase projects for infectious diseases.

Medivir is positioned uniquely among specialty pharmaceutical companies with a potential blockbuster Hepatitis C therapy in late-stage development, a marketed product, Xerclear(R)/Xerese(R), approaching international launch, a broad earlier pipeline and a solid financial position. Medivir will now remain focused on creating further shareholder value and continues to gain momentum in its strategic goal to become a profitable specialty pharmaceutical company. We look forward to sharing our exciting future news flow going forward with both our patients and our shareholders as we continue to build the growth in this business."

For the full Q3 report please visit For more information, please contact Rein Piir, CFO and VP, Investor Relations, mobile: +46(0)70-853-7292. Ron Long, CEO, phone: +46(0)8-5468-3113. Forthcoming financial information and calendar Financial Statement will be published on 22 February 2011. Three-month Interim Report will be published on 5 May 2011. Annual General Meeting will be held on 5 May 2011.

Additional information on Medivir's operations is available on the company's website,

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for ... of 217 pages published in November 2015 to ... online business intelligence library at . ... of the fastest growing global economies with a ...
(Date:11/24/2015)... LONDON , November 24, 2015 ... platform for scientists - since it was launched just six ... collaboration, reference management and authoring platform for scientists - since ... One million references have been loaded on to F1000Workspace ... for scientists - since it was launched just six months ...
(Date:11/24/2015)... , November 24, 2015 st  Scientific ... North America (RSNA) taking place in Chicago ... Booth 1122, Hall A. --> st  Scientific Assembly and ... (RSNA) taking place in Chicago ... Hall A. --> Molecular Dynamics will present its revolutionary ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Since its ... comprehensive solutions involving adult stem cell therapies to patients with chronic degenerative medical ... name as a Registered Trademark (RTM). , Organizations are required to hold a ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted ... to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ ... of time the doctor uses other traditional cutting tools, such as the scalpel and ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
Breaking Medicine News(10 mins):